Key result
An SVV-inactivated vaccine using BPL and adjuvants ISA 201 or IMS 1313 elicited humoral responses and protected finishing pigs against virulent SVV challenge.
Why the study?
Porcine idiopathic vesicular disease caused by Seneca Valley virus has frequently been prevalent in America and Southeast Asia, causing continuing issues.
Does an SVV-inactivated vaccine improve immunoreactivity and protection efficacy against virulent SVV challenge in finishing pigs?
Does an SVV-inactivated vaccine improve immunoreactivity and protection efficacy against virulent SVV challenge in finishing pigs?
An SVV-inactivated vaccine using β-propiolactone and IMS 1313 adjuvant provides effective humoral immunity and protection against virulent SVV challenge in finishing pigs.
Authors
No takes yet. Share an insight, caveat, or question.
SVV strain isolation extends PIVD virology data; leaves open vaccine development needs in affected swine populations.
Liu et al. (2022) studied Seneca Valley virus (SVV) infection. SVV-inactivated vaccine (SVV-BPL-201 and SVV-BPL-1313) was evaluated on Immunoreactivity and protection efficacy against virulent SVV challenge. An SVV-inactivated vaccine using BPL and adjuvants ISA 201 or IMS 1313 elicited humoral responses and protected finishing pigs against virulent SVV challenge.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: